Cardiopulmonary Exercise Testing Market Research Report - Global Forecast till 2027

Global Cardiopulmonary Exercise Testing Market: Information by Product (Cardiopulmonary Exercise Testing (CPET) Systems, Single-Photon Emission Computed Tomography (SPECT), Echocardiogram, Pulse Oximeters, Stress Blood Pressure Monitors and others), by End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/5163-CR | July 2019 | Region: Global | 157 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Overview


The Global Cardiopulmonary Exercise Testing Monitors Market is expected to register a CAGR of 5.80% to reach USD 3153.20 million till 2023.


Cardiopulmonary diseases are a wide range of severe disorders that affect the heart and lungs. The two primary stress-related cardiopulmonary diseases are cardiovascular diseases and chronic obstructive pulmonary disorders. Cardiovascular disorders are heart conditions that include diseased vessels, structural problems, and blood clots. The chronic obstructive pulmonary disease is a progressive lung disease characterized by the erratic deteriorating of symptoms, and these episodes are called acute exacerbations. The cardiopulmonary exercise testing is used to evaluate exercise capacity and predict outcome in patients with heart failure and other cardiac conditions. It provides an assessment of integrative exercise responses for the patients suffering from pulmonary, cardiovascular, and skeletal muscle systems.


The cardiopulmonary exercise testing market can be driven by the rising geriatric population, who are highly prone to chronic illnesses, rising prevalence of cardiovascular and respiratory system-related diseases, and advancements in technology.


Key Players


The prominent players in the global cardiopulmonary exercise testing market are Cardinal Health, COSMED SRL, GE Healthcare, Halma PLC, Hill-Rom Holdings, Inc., Koninklijke Philips NV, MGC Diagnostics Corporation, NIHON KOHDEN CORPORATION, Schiller AG, Masimo Corporation, and Vyaire Medical, Inc.


Intended Audience



  • MedTech companies

  • Government organizations

  • Research & consulting firms


Market Dynamics


The aging population is highly prone to degenerative diseases and chronic illnesses, which eventually leads to a rise in cardiovascular diseases. Moreover, the rising older population would lead to metabolic disorders such as diabetes and hypertension, which in turn increases the risk of chronic diseases such as cardiovascular disorders and respiratory disorders. For instance, Eurostat predicted that over 19.2% of the population in Europe was aged 65 and above. Additionally, according to the United States Census Bureau, around 49.2 million adults aged 65 and above were present in the US as of 2016. According to the United Nations, approximately 962 million people were aged over 60 and above, globally in 2017. The United Nations has also estimated that by 2050, the older population is likely to reach 425 million. This rise in the aging population will lead to a surge in hospital visits as this population is highly prone to various chronic disorders and is at a higher risk of developing complications which are also likely to drive the market.


Segmentation


The global cardiopulmonary exercise testing market, by product, has been segmented into cardiopulmonary exercise testing (CPET) systems, single-photon emission computed tomography (SPECT), echocardiogram, pulse oximeters, stress blood pressure monitors, and others. Based on end user, the cardiopulmonary exercise testing market has been categorized as hospitals & clinics, diagnostic centers, ambulatory surgical centers, and others.


Global Cardiopulmonary Exercise Testing Monitors Market Share, by Product, 2017 (%)  Cardiopulmonary Exercise Testing Market


Source: MRFR Analysis Regional Analysis


The global cardiopulmonary exercise testing market, on the basis of region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


The Americas accounted for the largest share in the global cardiopulmonary exercise testing market and is expected to continue to dominate during the forecast period from 2018 to 2023. The larger share is majorly attributed to the rising patient population that demands proper care and increasing adoption of early diagnostic practices in order to prevent cardiovascular disorders. Additionally, the rising prevalence of coronary artery diseases such as acute myocardial infarction and angina pectoris leading to the high demand for drugs and other medications, increase in awareness programs, the presence of major manufacturers, increasing awareness among the population, and high disposable income is driving the growth of the market. For instance, according to the American College of Cardiology, in 2015, around 422.7 million prevalent cases of cardiovascular disease were reported, and it accounted for one-third of all the deaths in 2015. Similarly, the American College of Cardiology stated that over 790,000 people in the US suffer from heart attacks every year. The Americas is also witnessing national educational programs to create awareness regarding cardiac diseases and their risk factors. For example, the National Heart, Lung, and Blood Institute (NHLBI) is sponsoring a national program called The Heart Truth in the US to create awareness regarding heart disease in women. This increasing number of patients suffering from chronic diseases, generate the requirement for quality devices and treatments, which attracts the attention of market players to grab the maximum share of the market for cardiopulmonary exercise testing.


The European market is the second-largest market for cardiopulmonary exercise testing. Factors such as a boost in the pharmaceutical sector in the European region, rising government initiatives to promote research to find a cure to the increasing number of cardiac disorders, improving economies, high disposable income per individual, and increased healthcare spending are driving the growth of the market in this region.


The Asia-Pacific region accounted for the third-largest market share due to a large number of the patient population, low manufacturing cost, low labor cost, developing healthcare infrastructure, and increased investments by the American and European market giants in Asian countries such as China and India.


The Middle East and Africa with less economic developments and meager income accounted for the least market share in 2017 but is expected to grow with the increasing awareness among people and with the demand for better healthcare facilities in countries along with the rising disposable income.


Global Cardiopulmonary Exercise Testing Market Share, by Region, 2017 (%)  Cardiopulmonary Exercise Testing Market


Source: MRFR Analysis


Some of the key strategies followed by players operating in the global cardiopulmonary exercise testing market were innovation, product development, and acquisition & mergers.



  • In March 2018, COSMED announced the release of a new line of metabolic monitors for quick, accurate, intuitive, and affordable indirect calorimetry.



  • In July 2018, GE Healthcare Korea installed its cyclotron with a complete PET radiopharmacy suite at the Korea Institute of Radiological & Medical Sciences (KIRAMS), making the nuclear medicine institute the world’s 400th cyclotron production facility under the GE brand.



  • In January 2017, Hill-Rom Holdings, Inc. acquired Mortara Instrument, Inc., a privately-held leader in diagnostic cardiology and patient monitoring solutions, technologies, and devices, for USD 330 million in cash. Hill-Rom anticipates that the structure of the acquisition will allow the company to qualify for a significant tax benefit, which at a net present value of approximately USD 40 million reduces the effective purchase price to approximately USD 290 million.


Market Segmentation


Global Cardiopulmonary Exercise Testing Market, by Product



  • Cardiopulmonary Exercise Testing (CPET) Systems

  • Single-Photon Emission Computed Tomography (SPECT)

  • Echocardiogram

  • Pulse Oximeters

  • Stress Blood Pressure Monitors

  • Others


Global Cardiopulmonary Exercise Testing Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Ambulatory Surgical Centers

  • Others


Global Cardiopulmonary Exercise Testing Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Reimbursement Scenarios of Cardiopulmonary Exercise Testing [CPX] Systems

  • Cardiopulmonary Exercise Testing Market, Industry Trends



Frequently Asked Questions (FAQ) :


The valuation would be USD 3153.2 million by 2023.

The Americas would ensure their domination during the forecast period.

Low cost of labor, developing healthcare, better funding from global players, and others would trigger growth.

The players involved are GE Healthcare, Cardinal Health, COSMED SRL, Hill-Rom Holdings, Inc., Halma PLC, MGC Diagnostics Corporation, Koninklijke Philips NV, Masimo Corporation, NIHON KOHDEN CORPORATION, Schiller AG, and Vyaire Medical, Inc.

The Global Cardiopulmonary Exercise Testing Market is a consistently growing one and will register a CAGR of 5.80% during the forecast period from 2018 to 2023. This projects a positive, yet moderate outlook. In 2017, the market was observed to have generated a value of USD 2,248.21 Mn which will appreciate as revenue generation increased to result in a market value of USD 3,153.20 Mn by the end of 2023.


The presence of advanced healthcare has resulted in longer lifespans for most people. As a result, there is a growing geriatric population across the globe. Aged individuals are susceptible to a variety of degenerative and chronic illnesses with cardiovascular diseases being amongst the most common. As such, cardiopulmonary exercise testing is a vital part of treatment as it is used to evaluate integrative response for patients such as exercise capacity and to assist in the prediction of outcome in patients suffering from pulmonary, and cardiovascular diseases among others. According to the US Census Bureau, more than 49 million adults over the age of 65 as of 2016. Moreover, the United Nations has predicted that by 2050, the global geriatric population is likely to reach an estimated 425 million. This indicates increased demand for cardiopulmonary exercise testing which is expected to continue growing. Moreover, cardiovascular diseases are on the rise and have been found to be the most common cause of premature mortality. The WHO has studied that 80% of deaths are caused due to cardiovascular disorders. The widespread adoption of unhealthy eating and exercise habits have increased the occurrence of cardiovascular problems which in turn, has increased the demand for cardiopulmonary exercise testing market.


Multiple products and tests are available in the market. However, cardiopulmonary exercise testing equipment comes with a high cost of maintenance, and require biomedical training among others. The rising costs of high-quality diagnostic devices is expected to challenge market growth. However, the high requirement of diagnostic equipment and proper healthcare in under-developed regions will likely serve as an opportunity for growth in the coming years as market players will look to establish a market presence in these regions.


The report has segmented the global cardiopulmonary exercise testing market on the basis of product, end-user, and region. Products used in the global market are segmented into echocardiogram, cardiopulmonary exercise testing (CPET) systems, pulse oximeters, stress blood pressure monitors, single-photon emission computed tomography (SPECT), and others. The CPET systems segment is projected to witness the highest CAGR of 6.26% over the review period due to the presence of a large patient pool suffering from ischemia combined with the ongoing innovations in product development. The segment 


End-users who employ cardiopulmonary exercise testing have been segmented into hospitals & clinics, diagnostic centers, ambulatory centers, and others. The hospitals & clinics segment accounts for the most significant segment in the global market. However, the diagnostic center's segment is anticipated to grow at the highest CAGR of 6.87% during the review period.


Regional Analysis


The Americas lead the global market in terms of growth due to its significant market size. The region is expected to retain its majority market share over the review period due to the presence of a rising patient population, a considerable portion of which is aged. Moreover, rising awareness regarding health care has increased the demand for early diagnostic practices, with patients becoming increasingly involved in their treatment and diagnosis process. The high rate of incidence of heart diseases, combined with the presence of prominent manufacturers as well as a high disposable income is expected to drive the market. The region has a well-established healthcare system which supports adoption of advanced medical devices for cardiopulmonary exercise testing. The European market accounts for the second most significant market in the global cardiopulmonary exercise testing market. The region’s rapidly expanding pharmaceutical sector, along with rising government initiatives to promote research and development of cardiac treatment & diagnosis. The region has similar growth drivers as those of the North American market.


Meanwhile, the Asia Pacific regions follow North America and Europe in terms of size and is expected to witness significant growth in the coming years. The region has a massive patient population which drives the demand for cardiopulmonary exercise testing. Healthcare investments are rising in the region due to the improvement of economic growth. Manufacturing giants from developed regions are increasingly investing in the APAC market due to the presence of low operational costs and lucrative opportunities for growth. China and India are leading country-level markets present in the APAC market.


Competitive Tracking


Schiller AG, Vyaire Medical Inc., GE Healthcare, MGC Diagnostics Corporation, Halma plc, NIHON KOHDEN CORPORATION, Koninklijke Philips N.V., Hill-Rom Holdings, Inc., COSMED srl, Cardinal Health, and Masimo Corporation are among the noted market players that have been included in the report. Key growth strategies used by these players to influence market growth include research & development, expansion of product portfolio and strategic acquisitions.

1 Report Prologue

2 Introduction

2.1 Definition 14

2.2 Scope of the Study 14

2.3 Research Objective 14

2.4 Assumptions & Limitations 14

2.4.1 Assumptions 14

2.4.2 Limitations 14

2.4.3 Market Structure 15

3 Research Methodology

3.1 Primary Research Methodology 17

3.2 Secondary Research Methodology 18

3.3 Market Size Estimation 19

3.4 Forecast Model 19

4 Market Dynamics

4.1 Introduction 22

4.2 Drivers 23

4.2.1 Rising Geriatric Population 23

4.2.2 Rising Cardiovascular Diseases 23

4.2.3 Research and Development 23

4.3 Restraints 24

4.3.1 High Cost 24

4.3.2 Regulatory Affairs 24

4.4 Opportunity 24

4.4.1 Entering Developing Markets 24

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 26

5.1.1 Bargaining Power of Suppliers 26

5.1.2 Bargaining Power of Buyers 26

5.1.3 Threat of New Entrants 26

5.1.4 Threat of Substitutes 27

5.1.5 Intensity of Rivalry 27

5.2 Price Analysis 27

5.3 Investment Opportunity Analysis 27

5.4 Value Chain Analysis 28

5.4.1 Supporting Activity 28

5.4.2 Inbound Logistics 28

5.4.3 Operations 28

5.4.4 Marketing and Sales 28

5.4.5 Outbound Logistics 28

5.4.6 Customer Services 29

6 Cardiopulmonary Exercise Testing Market, by Product

6.1 Introduction 31

6.2 Cardiopulmonary Exercise Testing (CPET) Systems 33

6.3 Single-Photon Emission Computed Tomography (SPECT) 34

6.4 Echocardiogram 34

6.5 Pulse Oximeters 35

6.6 Stress Blood Pressure Monitors 35

7 Cardiopulmonary Exercise Testing Market, by End-User

7.1 Introduction 37

7.2 Hospitals and Clinics 38

7.3 Diagnostic Centers 38

7.4 Ambulatory Centers 39

7.5 Others 39

8 Global Cardiopulmonary Exercise Testing Market, by Region

8.1 Introduction 41

8.2 Americas 42

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.2.1 North America 44

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.2.1.1 US. 46

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.2.1.2 Canada 47

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.2.2 South America 48

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3 Europe 49

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.1 Western Europe 51

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.1.1 Germany 53

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.1.2 France 54

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.1.3 UK 55

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.1.4 Italy 56

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.1.5 Spain 57

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.1.6 Rest of Western Europe 58

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.3.2 Eastern Europe 59

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.4 Asia-Pacific 60

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.4.1 Japan 62

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.4.2 China 63

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.4.3 India 64

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.4.4 Australia 65

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.4.5 South Korea 66

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.4.6 Rest of Asia-Pacific 67

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.5 Middle East and Africa 68

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.5.1 Middle East 70

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

8.5.2 Africa 71

Cardiopulmonary Exercise Testing Market, by Product

Cardiopulmonary Exercise Testing Market, by End-User

9 Company Landscape

9.1 Company Share Analysis 73

10 Company Profiles

10.1 Cardinal Health 75

10.1.1 Company Overview 75

10.1.2 Financial Overview 75

10.1.3 Products Offering 76

10.1.4 Key Developments 76

10.1.5 SWOT Analysis 76

10.1.6 Key Strategy 76

10.2 COSMED SRL 77

10.2.1 Company Overview 77

10.2.2 Financial Overview 77

10.2.3 Products Offering 77

10.2.4 Key Developments 77

10.2.5 SWOT Analysis 78

10.2.6 Key Strategy 78

10.3 GE Healthcare 79

10.3.1 Company Overview 79

10.3.2 Financial Overview (Healthcare Segment) 79

10.3.3 Products Offering 80

10.3.4 Key Developments 80

10.3.5 SWOT Analysis 80

10.3.6 Key Strategy 81

10.4 Halma PLC 82

10.4.1 Company Overview 82

10.4.2 Financial Overview 82

10.4.3 Products Offering 83

10.4.4 Key Developments 83

10.4.5 SWOT Analysis 83

10.4.6 Key Strategy 83

10.5 Hill-Rom Holdings, Inc. 84

10.5.1 Company Overview 84

10.5.2 Financial Overview 84

10.5.3 Products Offering 85

10.5.4 Key Developments 85

10.5.5 SWOT Analysis 85

10.5.6 Key Strategy 85

10.6 Koninklijke Philips NV. 86

10.6.1 Company Overview 86

10.6.2 Financial Overview 86

10.6.3 Products Offering 87

10.6.4 Key Developments 88

10.6.5 SWOT Analysis 88

10.6.6 Key Strategy 88

10.7 MGC Diagnostics Corporation 89

10.7.1 Company Overview 89

10.7.2 Financial Overview 89

10.7.3 Products Offering 89

10.7.4 Key Developments 89

10.7.5 SWOT Analysis 90

10.7.6 Key Strategy 90

10.8 NIHON KOHDEN CORPORATION 91

10.8.1 Company Overview 91

10.8.2 Financial Overview 91

10.8.3 Products Offering 92

10.8.4 Key Developments 92

10.8.5 SWOT Analysis 92

10.8.6 Key Strategy 92

10.9 Schiller AG 93

10.9.1 Company Overview 93

10.9.2 Financial Overview 93

10.9.3 Products Offering 93

10.9.4 Key Developments 94

10.9.5 SWOT Analysis 94

10.9.6 Key Strategy 94

10.10 Masimo Corporation 95

10.10.1 Company Overview 95

10.10.2 Financial Overview 95

10.10.3 Products Offering 96

10.10.4 Key Developments 96

10.10.5 SWOT Analysis 96

10.10.6 Key Strategy 97

10.11 Vyaire Medical, Inc. 98

10.11.1 Company Overview 98

10.11.2 Financial Overview 98

10.11.3 Products Offering 98

10.11.4 Key Developments 98

10.11.5 SWOT Analysis 99

10.11.6 Key Strategy 99

11 Appendix

11.1 Discussion Blue Print 101

11.2 References 102

12 List of Tables

TABLE 1 PRIMARY INTERVIEWS 18

TABLE 2 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 31

TABLE 3 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR CARDIOPULMONARY EXERCISE TESTING (CPET) SYSTEMS,

BY REGION, 2020–2027 (USD MILLION) 32

TABLE 4 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR SINGLE–PHOTON EMISSION COMPUTED

TOMOGRAPHY (SPECT), BY REGION, 2020–2027 (USD MILLION) 33

TABLE 5 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR ECHOCARDIOGRAM, BY REGION, 2020–2027 (USD MILLION) 33

TABLE 6 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR PULSE OXIMETERS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 7 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR STRESS BLOOD PRESSURE MONITORS, BY REGION,

2020–2027 (USD MILLION) 34

TABLE 8 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 36

TABLE 9 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR HOSPITALS AND CLINICS, BY REGION,

2020–2027 (USD MILLION) 37

TABLE 10 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR DIAGNOSTIC CENTERS, BY REGION,

2020–2027 (USD MILLION) 37

TABLE 11 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET FOR AMBULATORY CENTERS, BY REGION,

2020–2027 (USD MILLION) 38

TABLE 12 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020–2027 (USD MILLION) 40

TABLE 13 AMERICAS CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020–2027 (USD MILLION) 41

TABLE 14 AMERICAS CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 42

TABLE 15 AMERICAS CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 42

TABLE 16 NORTH AMERICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY 2020–2027 (USD MILLION) 43

TABLE 17 NORTH AMERICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 44

TABLE 18 NORTH AMERICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 44

TABLE 19 US CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 45

TABLE 20 US CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 45

TABLE 21 CANADA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 46

TABLE 22 CANADA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 46

TABLE 23 SOUTH AMERICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 47

TABLE 24 SOUTH AMERICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 47

TABLE 25 EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020–2027 (USD MILLION) 48

TABLE 26 EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 49

TABLE 27 EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 49

TABLE 28 WESTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY 2020–2027 (USD MILLION) 50

TABLE 29 WESTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 51

TABLE 30 WESTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 51

TABLE 31 GERMANY CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 52

TABLE 32 GERMANY CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 52

TABLE 33 FRANCE CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 53

TABLE 34 FRANCE CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 53

TABLE 35 UK CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 54

TABLE 36 UK CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 54

TABLE 37 ITALY CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 55

TABLE 38 ITALY CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 55

TABLE 39 SPAIN CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 56

TABLE 40 SPAIN CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 56

TABLE 41 REST OF WESTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 57

TABLE 42 REST OF WESTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 57

TABLE 43 EASTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 58

TABLE 44 EASTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 58

TABLE 45 ASIA-PACIFIC CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY 2020–2027 (USD MILLION) 59

TABLE 46 ASIA-PACIFIC CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 60

TABLE 47 ASIA-PACIFIC CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 60

TABLE 48 JAPAN CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 61

TABLE 49 JAPAN CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 61

TABLE 50 CHINA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 62

TABLE 51 CHINA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 62

TABLE 52 INDIA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 63

TABLE 53 INDIA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 63

TABLE 54 AUSTRALIA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 64

TABLE 55 AUSTRALIA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 64

TABLE 56 SOUTH KOREA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 65

TABLE 57 SOUTH KOREA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 65

TABLE 58 REST OF ASIA-PACIFIC CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 66

TABLE 59 REST OF ASIA-PACIFIC CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 66

TABLE 60 MIDDLE EAST & AFRICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020–2027 (USD MILLION) 67

TABLE 61 MIDDLE EAST & AFRICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 68

TABLE 62 MIDDLE EAST & AFRICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 68

TABLE 63 MIDDLE EAST CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 69

TABLE 64 MIDDLE EAST CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 69

TABLE 65 AFRICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020–2027 (USD MILLION) 70

TABLE 66 AFRICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY END–USER 2020–2027 (USD MILLION) 70

13 List of Figures

FIGURE 1 TOP-DOWN & BOTTOM-UP APPROACHES 19

FIGURE 2 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET 21

FIGURE 3 PORTER’S FIVE FORCES MODEL 25

FIGURE 4 VALUE CHAIN: CARDIOPULMONARY EXERCISE TESTING MARKET 27

FIGURE 5 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY PRODUCT 2020 & 2027 (USD MILLION) 30

FIGURE 6 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY END-USER 2020 & 2027 (USD MILLION) 36

FIGURE 7 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020 & 2027 (USD MILLION) 40

FIGURE 8 AMERICAS CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020 (%) 41

FIGURE 9 NORTH AMERICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY 2020 (%) 43

FIGURE 10 EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020 (%) 48

FIGURE 11 WESTERN EUROPE CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY 2020 (%) 50

FIGURE 12 ASIA-PACIFIC CARDIOPULMONARY EXERCISE TESTING MARKET, BY COUNTRY 2020(%) 59

FIGURE 13 MIDDLE EAST & AFRICA CARDIOPULMONARY EXERCISE TESTING MARKET, BY REGION 2020 (%) 67

FIGURE 14 GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET COMPANY SHARE ANALYSIS, 2020 (%) 72



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Company Landscape


Company Share Analysis


Globally there are various players operating in this market. With a well-established market in the American region, major companies have their homes in the region and generate maximum market share. These companies have expanded their operating units in various other regions as well. Moreover, there are other small and medium scale players that generate revenue from the local market.

GLOBAL Cardiopulmonary Exercise Testing MARKET COMPANY SHARE ANALYSIS, 2017 (%)


GLOBAL CARDIOPULMONARY EXERCISE TESTING MARKET COMPANY SHARE ANALYSIS, 2017 (%)


Source: Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


The above diagram displays the market share generated by the companies in the global cardiopulmonary exercise testing market in the year 2017. The major part of the market share is accounted by top three companies with 40.6% share of the global cardiopulmonary exercise testing market. The global cardiopulmonary exercise testing market is led by GE healthcare with 20.8% of the global market share followed by Koninklijke Philips N.V. with 14.4%, and Vyaire Medical Inc. being the third largest with  5.3% of the market share.


GE Healthcare is one of the leading players in the field of cardiopulmonary exercise testing. The firm accounted for over 20.8% share in 2017. The major reason for its growth is its wide range of operating segments and wide application areas. The firm has a separate healthcare segment, which provides healthcare diagnostic imaging and clinical systems, life sciences products and services, and digital solutions to over 180 countries. Additionally, the firm has manufacturing operations in over 191 manufacturing plants located in 38 states in the US and Puerto Rico.


Koninklijke Philips N.V. contributes to approximately 14.4% of the global cardiopulmonary exercise testing market. The firm has been largely focusing on research and development to enhance its product portfolio. For instance, the firm invested around 9.9% of sales on research and development. The firm operates in over 75 countries globally with R&D sites in the Americas, Asia, and Europe.


Vyaire Medical Inc. accounted for the third largest spot with 9.77% of the market share. The firm has a huge geographic presence due to its 27,000 unique products for the diagnosis, treatment, and monitoring of respiratory conditions. The firm offers products through its four operating areas, namely,  respiratory diagnostics, ventilation, airway management, and operative care consumables.